staceywhite, Author at European Medical Journal - Page 76 of 195

Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia

For many patients diagnosed with acute myeloid leukaemia (AML), long-term survival remains elusive….

EMJ Hepatology 10.1 Feature Image

Prescription Event Monitoring of Checkpoint Inhibitor-Induced Liver Injury and Outcomes of Rechallenge: A 10-Year Experience

The definition and severity of checkpoint inhibitor-induced liver injury (ChILI) have been reported using the Common Terminology Criteria for Adverse Events (CTCAE) used in cancer therapy.

EMJ Hepatology 10.1 Feature Image

Management of Severe, Steroid-Resistant and Steroid-Refractory Hepatotoxicity in Patients Treated with Checkpoint Inhibitor Immunotherapy

Checkpoint inhibitor immunotherapy (ICI) has revolutionised cancer care but is associated with immune-related toxicities, which may require ICI discontinuation and immunosuppressive therapies (IST).

Congress Interview - Aleksander Krag

EASL 2022 Congress Interview: Aleksander Krag

Hepatology is an exciting and challenging clinical discipline with many great research opportunities and a vibrant international community.

EMJ Hematology 10.1 2022 Feature Image

EHA 2022 Abstract Highlights

The following highlights focus on several insightful and innovative abstracts at the European Hematology Association (EHA) 2022 hybrid…

Feature Image Cardio Supp 3

Personalised Approach to Atherosclerotic Cardiovascular Disease: The Future is Here

This plenary session began with a focus on cutting edge research into the role of the immune system in atherosclerotic cardiovascular dise…

Rheumaology 9.1 Feature Image

Review of the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress

A NEW and innovative hybrid format was adopted for the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress, allowing…

Rheumaology 9.1 Feature Image

Difficult-to-Treat Rheumatoid Arthritis

At this year’s European Alliance of Associations for Rheumatology (EULAR) Congress, taking place on 1st–4th June, Jacob van Laar Professor…

Editor’s Pick: Impact of COVID-19 on Diagnostic Delay in Rare Disease

Rare diseases are individually rare but collectively common, with a combined prevalence of 3.5–5.9%. A common feature of many diseases is a substantial delay in patients receiving a correct diagnosis; this protracted path to diagnosis is termed ‘the diagnostic odyssey’.

Salvatore Brugaletta

EuroPCR 2022 Congress Interview: Salvatore Brugaletta

Salvatore Brugaletta Senior Consultant Interventional Cardiologist, University Hospital Clinic, Barcelona, Spain; Associate Professor, Uni…